Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.
Meir Wetzler, Clara D. Bloomfield(North Shore University Hospital), Leslie E. Blumenson(Roswell Park Comprehensive Cancer Center), Krzysztof Mrózek(The Ohio State University), Maurice Barcos(Roswell Park Comprehensive Cancer Center), CC Stewart, AnneMarie W. Block(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Steven H. Bernstein(University of Rochester), Geoffrey P. Herzig(Washington University in St. Louis), Maria R. Baer(University of Maryland, Baltimore)
Cited by 41
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k